Trinity Biotech (TRIB) Competitors $1.69 -0.07 (-3.98%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends TRIB vs. CTXR, VRCA, ENTX, STTK, IMRX, AVTE, EVOK, RPHM, MURA, and KRONShould you be buying Trinity Biotech stock or one of its competitors? The main competitors of Trinity Biotech include Citius Pharmaceuticals (CTXR), Verrica Pharmaceuticals (VRCA), Entera Bio (ENTX), Shattuck Labs (STTK), Immuneering (IMRX), Aerovate Therapeutics (AVTE), Evoke Pharma (EVOK), Reneo Pharmaceuticals (RPHM), Mural Oncology (MURA), and Kronos Bio (KRON). These companies are all part of the "pharmaceutical products" industry. Trinity Biotech vs. Citius Pharmaceuticals Verrica Pharmaceuticals Entera Bio Shattuck Labs Immuneering Aerovate Therapeutics Evoke Pharma Reneo Pharmaceuticals Mural Oncology Kronos Bio Trinity Biotech (NASDAQ:TRIB) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking. Does the MarketBeat Community prefer TRIB or CTXR? Trinity Biotech received 127 more outperform votes than Citius Pharmaceuticals when rated by MarketBeat users. Likewise, 72.04% of users gave Trinity Biotech an outperform vote while only 62.28% of users gave Citius Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTrinity BiotechOutperform Votes33572.04% Underperform Votes13027.96% Citius PharmaceuticalsOutperform Votes20862.28% Underperform Votes12637.72% Does the media refer more to TRIB or CTXR? In the previous week, Trinity Biotech had 1 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 1 mentions for Trinity Biotech and 0 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 0.00 beat Trinity Biotech's score of -0.39 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Trinity Biotech Neutral Citius Pharmaceuticals Neutral Do insiders & institutionals believe in TRIB or CTXR? 79.0% of Trinity Biotech shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 8.2% of Trinity Biotech shares are owned by company insiders. Comparatively, 15.0% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend TRIB or CTXR? Citius Pharmaceuticals has a consensus target price of $4.00, suggesting a potential upside of 1,014.52%. Given Citius Pharmaceuticals' higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Trinity Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Trinity Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/ACitius Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Which has higher earnings and valuation, TRIB or CTXR? Trinity Biotech has higher revenue and earnings than Citius Pharmaceuticals. Citius Pharmaceuticals is trading at a lower price-to-earnings ratio than Trinity Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTrinity Biotech$56.83M0.23-$24.02M-$2.70-0.63Citius PharmaceuticalsN/AN/A-$32.54M-$0.24-1.50 Which has more volatility & risk, TRIB or CTXR? Trinity Biotech has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.61, indicating that its share price is 61% more volatile than the S&P 500. Is TRIB or CTXR more profitable? Citius Pharmaceuticals has a net margin of 0.00% compared to Trinity Biotech's net margin of -38.02%. Trinity Biotech's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Trinity Biotech-38.02% N/A -26.62% Citius Pharmaceuticals N/A -44.65%-39.39% SummaryTrinity Biotech beats Citius Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Ad Crypto 101 MediaMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…All you have to do is claim your free ticket to the event now… Get Trinity Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for TRIB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TRIB vs. The Competition Export to ExcelMetricTrinity BiotechDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.88M$2.31B$5.40B$8.53BDividend YieldN/A0.69%5.15%4.14%P/E Ratio-0.634.92112.5515.07Price / Sales0.2341.611,478.8293.55Price / CashN/A16.3539.8334.04Price / Book-0.543.164.645.01Net Income-$24.02M$29.98M$119.13M$225.46M7 Day Performance-12.44%-3.56%0.78%0.37%1 Month Performance43.22%-0.60%5.65%3.57%1 Year Performance-24.55%-2.99%36.90%29.42% Trinity Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TRIBTrinity Biotech0.7 of 5 stars$1.69-4.0%N/A-24.6%$12.88M$56.83M-0.63480Gap UpCTXRCitius Pharmaceuticals2.301 of 5 stars$0.37+2.8%$4.00+981.4%-53.4%$66.83MN/A-1.5420Positive NewsVRCAVerrica Pharmaceuticals4.1911 of 5 stars$1.56+3.3%$11.40+630.8%-58.1%$66.57M$5.12M-0.8340Gap UpENTXEntera Bio2.8872 of 5 stars$1.86-1.1%$10.00+437.6%+170.4%$66.56M$57,000.00-7.1520Short Interest ↓Gap UpSTTKShattuck Labs3.5867 of 5 stars$1.36+3.0%$8.67+539.6%-22.4%$64.67M$1.66M-0.73100Gap DownIMRXImmuneering3.7702 of 5 stars$2.14+6.5%$12.60+488.8%-71.1%$63.46M$320,000.00-1.1260Short Interest ↓News CoveragePositive NewsAVTEAerovate Therapeutics1.5464 of 5 stars$2.18+2.8%$2.25+3.2%-73.8%$62.83MN/A-0.6951News CoverageEVOKEvoke Pharma0.7294 of 5 stars$7.08+33.6%N/A-59.7%$60.87M$7.53M-0.444Gap UpHigh Trading VolumeRPHMReneo Pharmaceuticals2.3163 of 5 stars$1.82+5.2%$11.01+505.1%-76.8%$60.84MN/A-0.8430Gap DownMURAMural Oncology3.7954 of 5 stars$3.63+3.4%$16.00+340.8%N/A$59.80MN/A-0.35119KRONKronos Bio3.5633 of 5 stars$0.98+1.0%$4.13+321.3%+17.4%$59.03M$6.29M-0.56100Short Interest ↓News Coverage Related Companies and Tools Related Companies Citius Pharmaceuticals Competitors Verrica Pharmaceuticals Competitors Entera Bio Competitors Shattuck Labs Competitors Immuneering Competitors Aerovate Therapeutics Competitors Evoke Pharma Competitors Reneo Pharmaceuticals Competitors Mural Oncology Competitors Kronos Bio Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TRIB) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trinity Biotech plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Trinity Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
